<span item_type="fundamental" item_id="a8231a4a70d176de41bc47bc37254b6f" counter_id="ST/US/ISPC" env="prod"></span><span item_type="announcement" item_id="583890265315868801" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 106.59 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.48.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -2.831 M.</p><p></p><h3>Revenue</h3><ul><li>Revenue for the nine months ended September 30, 2025, was $1,877,237, a decrease of 76% from $7,815,608 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li></ul><h3>Operating Expenses</h3><ul><li>Total operating expenses for the nine months ended September 30, 2025, were $8,167,274, a decrease of 44% from $14,703,197 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>Cost of revenue decreased by 67% to $1,306,049 from $3,978,557.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>Technology expenses decreased by 37% to $1,632,782 from $2,578,624.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>Sales and marketing expenses decreased by 27% to $1,746,424 from $2,380,515.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>Supply development expenses decreased by 49% to $215,144 from $420,322.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>Fulfillment costs decreased by 46% to $695,772 from $1,293,185.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>General and administrative expenses decreased by 37% to $2,571,103 from $4,051,994.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li></ul><h3>Loss from Operations</h3><ul><li>Loss from operations for the nine months ended September 30, 2025, was $6,290,037, a decrease of 9% from $6,887,589 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li></ul><h3>Other Income, Net</h3><ul><li>Other income, net, increased by 84% to $803,750 from $436,595.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss for the nine months ended September 30, 2025, was $5,486,287, a decrease of 15% from $6,450,994 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was $3,323,685 for the nine months ended September 30, 2025, compared to $4,691,032 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>Net cash used in investing activities was $1,000,454 for the nine months ended September 30, 2025, compared to net cash provided by investing activities of $2,052,614 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>Net cash provided by financing activities was $5,228,489 for the nine months ended September 30, 2025, compared to $2,046,606 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company plans to improve sales and revenues while significantly reducing and managing expenditures to improve its financial position and ensure continued funding of operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li><li>Management’s plan to mitigate conditions that raise substantial doubt about the company’s ability to continue as a going concern includes generating additional revenues, deferring certain projects and capital expenditures, and eliminating certain future operating expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1558569/000121390025111547/ea0265830-10q_ispecimen.htm"></span></li></ul>

iSpecimen | 10-Q: FY2025 Q3 Revenue: USD 106.59 K